Exome Asset Management
Exome Asset Management reported 52 stocks worth $162M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are GH (6.3%), PRAX (5.6%) and TGTX (5.6%). Compared with Q1 2026, the fund opened new positions in TGTX, ABVX and QURE, added to MAZE, trimmed GH, PRAX and COGT and sold out of ELV, AVTX and FDMT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  GH Guardant Health Inc | $10.1M | 6.3% | 68K | −15K (−18%) | 8 of 8 | |
| 2 |  PRAX Praxis Precision Medicines I | $9.1M | 5.6% | 27K | −18K (−40%) | 5 of 8 | |
| 3 |  TGTX TG Therapeutics Inc | $9.1M | 5.6% | 165K | New position | 2 of 8 | |
| 4 |  COGT Cogent Biosciences Inc | $8.1M | 5.0% | 211K | −68K (−24%) | 6 of 8 | |
| 5 |  IONS Ionis Pharmaceuticals Inc | $7M | 4.3% | 88K | −22K (−20%) | 7 of 8 | |
| 6 |  LLY Eli Lilly & Co | $6.6M | 4.1% | 5,492 | −1,520 (−22%) | 8 of 8 | |
| 7 |  ABVX Abivax SA | $6.2M | 3.9% | 47K | New position | 1 of 8 | |
| 8 |  ALMS Alumis Inc | $5.8M | 3.5% | 204K | −75K (−27%) | 4 of 8 | |
| 9 |  CYTK Cytokinetics Inc | $5.1M | 3.2% | 60K | −44K (−42%) | 8 of 8 | |
| 10 |  ELVN Enliven Therapeutics Inc | $5.1M | 3.1% | 100K | −120K (−54%) | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 ELV Elevance Health Inc | $4.3M | 15K |
APELLIS PHARMACEUTICALS INC | $3.4M | 86K |
 AVTX Avalo Therapeutics Inc | $2.4M | 159K |
SOLENO THERAPEUTICS INC | $2.1M | 62K |
 FDMT 4D Molecular Therapeutics in | $1.2M | 131K |
🔒 Free account: see all 8.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Exome Asset Management 13F FAQ
What does Exome Asset Management own?
Exome Asset Management reported 52 stocks worth $162M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are GH (6.3%), PRAX (5.6%) and TGTX (5.6%). The table above lists every position in the filing (the top 10 without an account).
What did Exome Asset Management buy and sell in Q2 2026?
Compared with Q1 2026: 15 new positions, 1 added to, 32 trimmed and 8 sold out. New positions include TGTX, ABVX and QURE. It sold all of ELV, AVTX and FDMT.
When will Exome Asset Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Exome Asset Management's portfolio worth?
The Q2 2026 filing reports $162M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.